select semaglutide trial What the of means for clinicians Semaglutide and cardiovascular outcomes in

Produced by the L-cells in the intestine in response to food intake, GLP-1 acts as a master regulator of metabolic function

Addressing these challenges while capitalizing on innovations in drug design will be essential for optimizing patient outcomes and realizing the full potential of GLP-1based therapies

Sultan, is not only safe but can also be life changing

Beyond cholesterol numbers, semaglutide reduces systemic inflammation markers and improves insulin resistance, both of which contribute to atherosclerotic disease

doi: 10.1007/s11033-016-3942-x 88 LiuMFuMYangXJiaGShiXJiJet al

The p-values reported in all figures come from the hypothesis testing for the Kaplan-Meier survival curves and were conducted using the log-rank test